Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells.

about

Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma.Challenges in validating candidate therapeutic targets in cancer.

P2860

Q49869942-E1545155-42C8-4902-A471-58B6F89A2684 Q50123858-7A6CF15A-3BB1-4CBC-994A-9C19AF98A330

P2860

Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells.

Item

http://www.wikidata.org/entity/Q41085328

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Anti-myeloma activity of MELK ...... ent of malignant plasma cells.

@en

type

Item

label

Anti-myeloma activity of MELK ...... ent of malignant plasma cells.

@en

prefLabel

Anti-myeloma activity of MELK ...... ent of malignant plasma cells.

@en

P1476

Anti-myeloma activity of MELK ...... ment of malignant plasma cells

@en

P2093

A J Jakubowiak

http://www.w3.org/2001/XMLSchema#string

J-H Park

http://www.w3.org/2001/XMLSchema#string

S Chung

http://www.w3.org/2001/XMLSchema#string

S Rosebeck

http://www.w3.org/2001/XMLSchema#string

Y Matsuo

http://www.w3.org/2001/XMLSchema#string

Y Nakamura

http://www.w3.org/2001/XMLSchema#string

P2860

Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance

Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer.

The molecular classification of multiple myeloma

Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells.

MELK-a conserved kinase: functions, signaling, cancer, and controversy.

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.

Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1

MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells.

Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.

Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.

P2888

bcj.2016.71

P304

e460

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BCJ.2016.71

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

A T Stefka

P577

2016-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1017440388

http://www.w3.org/2001/XMLSchema#string

P698

27540718

http://www.w3.org/2001/XMLSchema#string

P932

5022182

http://www.w3.org/2001/XMLSchema#string

Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells.

about

P2860

P2860

Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932